用于向蛋白质降解的细胞内方法评估E3结合酶
Yunan Zheng1, Anamika Singh2, Zeqi Niu1
1Technology & Therapeutic Platforms, AbbVie Inc., North Chicago, Illinois 60064, United States.
Journal of the American Chemical Society
|June 10, 2025
概括
这项研究引入了一种使用遗传密码扩展的新方法,以创建针对蛋白质降解的E3联结合体结构. 这个平台可以探索和开发新的治疗策略,
科学领域:
- 生物化学
- 分子生物学
- 化学生物学
背景情况:
- 由于缺乏特定的结合剂,因此难以评估针对蛋白质降解 (TPD) 的E3结合酶.
- 开发新的方法来创建功能性的E3酶结合体结构对于推进TPD疗法至关重要.
研究的目的:
- 使用遗传密码扩展和点击化学创建共价E3联结体构造的多功能平台.
- 证明这个平台用于绘制新基质的 E3 连接表面并使新基质的 TPD 有效,包括没有已知的连接体的连接体.
主要方法:
- 利用遗传密码扩展将含有四素的非正规氨基酸 (Tet-ncAA) 纳入活细胞表达的E3链酶.
- 采用点击化学,将Tet-ncAA与压力trans-cyclooctene (sTCO) 结合的新基质结合剂结合起来.
- 应用开发的E3无联体降解剂 (ELF降解剂) 平台对cereblon (CRBN) 和斑点型POZ蛋白 (SPOP) E3联体.
主要成果:
- 通过工程 CRBN 连接酶证明了新基质的成功 TPD,其效率取决于 Tet-ncAA 放置和链接器长度.
- 展示了平台的功能地图E3表面和确定最佳的TPD接口的能力.
- 成功地将该策略应用于SPOP,一种缺乏已知的特定联体的E3,揭示了其TPD应用和PROTAC类开发的潜力.
结论:
- 无E3联体降解剂 (ELF降解剂) 平台提供了定义功能降解点和指导降解剂设计的多功能方法.
- 这种方法可以在活细胞中查询任何E3连接酶表面,并且适用于广泛的E3连接酶.
- 该ELF降解平台释放新的E3连接酶,包括没有已知的连接体的E3,用于针对蛋白质降解的治疗应用.
相关概念视频
02:58Regulated Protein Degradation
7.2K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.2K
01:13The Proteasome
817
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
817